PHARMENTERPRISES LLC
11
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
11%
1 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis
Role: lead
Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers.
Role: lead
Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19
Role: lead
Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia
Role: lead
Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI
Role: lead
Study to Assess Safety, Tolerability and Pharmacokinetics of Treamid in Healthy Volunteers
Role: lead
Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections
Role: lead
Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers
Role: lead
XC8 in the Treatment of Patients With Bronchial Asthma
Role: lead
XC8 in the Treatment of Patients With Acute Respiratory Viral Infection
Role: lead
XC8 Safety, Tolerability and Pharmacokinetics in Healthy Volunteers
Role: lead
All 11 trials loaded